Stream Link: https://globalmeet.webcasts.com/starthere.jsp?ei=1669397&tp_key=ff751ba4f1
A PTCE encore virtual symposium affiliated with the 2024 HOPA Annual Conference.
Program Description
Cytogenetic risk classification based on routine blood tests forms the basis of the standard treatment paradigm in lower-risk MDS (LR-MDS) and requires the involvement of oncology pharmacists to individualize treatment management. Treatment goals center on symptom improvement and achieving transfusion independence, yet patients with MDS frequently experience complications, including anemia with transfusion dependence, transfusional iron overload requiring iron chelation therapy, and disease progression/leukemic transformation, among others. Several recently approved and emerging agents could overcome and mitigate these challenges as alternatives to erythropoiesis-stimulating agents and red blood cell transfusions. Clinical pharmacists within oncology practice settings play key roles in implementing novel therapies into treatment paradigms as they contribute to updates of treatment and education protocols, provide patient counseling, and assist with supportive care for newly approved therapies. This educational activity will center around recent and relevant data to provide oncology pharmacists with up-to-date information and insights into newly emerging therapies and treatment protocols in LR-MDS. Included patient case discussions will establish the role of oncology pharmacists in symptom improvement, enhancing quality of life, and prolonging survival for patients with LR-MDS.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 22, 2024
Expiration date: July 22, 2024
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate the efficacy and clinical utility of emerging treatment strategies for lower-risk myelodysplastic syndromes (LR-MDS) through the interpretation of recent and emerging clinical evidence
- Construct personalized treatment plans for patients with LR-MDS considering patient preference and disease-related complications
- Optimize systemic therapy for patients with LR-MDS through appropriate dosing and therapeutic adjustments relative to treatment response and tolerability
- Practice with interdisciplinary health care teams to ensure the seamless integration of supportive care interventions into the overall LR-MDS patient care plan
Anthony J. Perissinotti, PharmD, BCOP
Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan
Firas El Chaer, MD
Assistant Professor of Medicine
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia
Rachel Feaster, PharmD, BCOP, BCPS
Clinical Oncology Pharmacist
Fred Hutchinson Cancer Center
Seattle, Washington
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-114-L01-P. The activity is available for CE credit through July 22, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Anthony J. Perissinotti, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Servier, Amgen, AbbVie
Firas El Chaer, MD, has the following financial relationships with commercial interests to disclose:
Consultant: SPD Oncology, Amgen, CTI BioPharma, AbbVie, MorphoSys, Association of Community Cancer Centers, PharmaEssentia, BMS
Other Support: Amgen, Celgene, SPD Oncology, Sanofi, Bristol Myers Squibb, FibroGen, PharmaEssentia, BioSight, MEI Pharma, Norvartis, Arog Pharmaceuticals
Rachel Feaster, PharmD, BCOP, BCPS, has the following financial relationship with a commercial interest to disclose:
Other: freelance medical writing at GoodRx
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Daphne Davis, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Former employee: GSK
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms